We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Sigma Labs Inc | NASDAQ:SGLB | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.05 | 1.03 | 1.07 | 0 | 01:00:00 |
Second Quarter 2017 Business Highlights and Recent Developments
“We are implementing our strategic double down on both Sigma Labs' technology and also on our ongoing efforts to grow Sigma Labs into a robust digital 3D ecosystem by seeking to identify compatible businesses to potentially acquire that will be synergistic with Sigma Labs' technology and business, although there are currently no agreements with respect to the acquisition by the Company of any third party, and there is no assurance than any acquisition will be consummated. In July and early August 2017, we changed our management lineup to add more capacity to implement our strategy. We believe that we have excellent technology and are supported by an excellent team of technologists. We also believe that we have accomplished a hard-won understanding of a rapidly changing market place, and that our early adopter and OEM strategies are gaining traction. We know that we need to perform better operationally, and are reconstituting senior management and the Board to focus on three very defined targets: (1) product development, sales, and support; (2) business operations; and (3) expansion through the exploration of various business opportunities," said John Rice, interim CEO.
Second Quarter Ended June 30, 2017 Financial Results
Revenue for the three months ended June 30, 2017, was $290,553, as compared to revenue of $93,824 during the same period in 2016. The increase in revenue was primarily due to new contracts in 2017, including Honeywell DARPA Phase III, Aerojet Rocketdyne, and Solar Turbines, Pratt and Whitney, and Woodward which accounted for the majority of the $196,729 increase in revenues when comparing Q2 2017 to Q2 2016. In addition, the Q2 2016 revenues were lower due to the completion of the GEA America Makes Program in Q1 2016, providing no revenues from that contract in Q2 2016.
General and Administrative expenses for the three months ended June 30, 2017, were $594,193, as compared to $480,697 for the same period in 2016. The $113,496 increase was primarily due to increases in legal fees and the increase in interest and finance costs on the $1,000,000 promissory note originated in October 2016. Payroll expenses for the three months ended June 30, 2017, were $300,661, as compared to $252,895 for the same period in 2016. The $47,766 increase was due to an increase in employees in Q2 2017 versus Q2 2016. Expenses relating to stock-based compensation for the three months ended June 30, 2017, were $166,773, as compared to $59,362 for the same period in 2016. The $107,411 increase was due to more stock and stock options being used to pay for services as a mechanism to preserve cash. Research and Development expenses for the three months ended June 30, 2017, were $118,853, as compared to $11,907 for the same period in 2016. The $106,946 increase was the result of continued improvement and development of the Company's software and technology.
Net loss for the three months ended June 30, 2017 increased $246,895 and totaled $988,741, as compared to $741,846 for the same period in 2016. The increase is primarily due to the $375,619 increase in expenses noted above, partially offset by the $116,221 increase in gross profits, which is primarily due to the $196,729 increase in revenues in Q2 2017 compared to Q2 2016.
Revenue for the six months ended June 30, 2017, was $440,756, as compared to $452,279 recognized during the same period in 2016. The $11,523 decrease in revenue was primarily due to the completion of the GEA America Makes Program in 2016, providing three months of revenue in 2016 but no revenue in 2017. However, new business in Q2 2017 from customers like Honeywell DARPA Phase III, Aerojet Rocketdyne and Solar Turbines made up for the majority of the reduction that resulted from the completion of the GEA America Makes Program. The Company financed its operations during the six months ended June 30, 2017 and 2016 primarily from PrintRite3D® system sales, DARPA Phase III, Aerojet Rocketdyne and Solar Turbines programs, engineering consulting services provided to third parties, and through sales of the Company's common stock and debt securities.
General and Administrative expenses for the six months ended June 30, 2017, were $1,237,988, as compared to $876,185 for the same period in 2016. The costs of the February 2017 public offering that generated net proceeds of approximately $5.25 million, legal fees, and the interest and finance costs related to the Company's $1,000,000 note, are the primary reasons for the $361,803 increase in G&A expenses. Payroll expenses for the six months ended June 30, 2017, were $677,282, as compared to $468,484 for the same period in 2016. Employee additions are the main reason for the $208,798 payroll expense increase. Expenses relating to stock-based compensation for the six months ended June 30, 2017, were $306,405, as compared to $130,913 for the same period in 2016. The $175,492 increase is the result of using stock and stock options to pay for services in order to preserve cash. Research and Development expenses for the six months ended June 30, 2017, were $167,615, as compared to $50,978 for the same period in 2016. The $116,637 increase is the result of increased efforts to continue to develop and improve the Company's software and technology.
Net loss for the six months ended June 30, 2017, increased $720,193 over the prior year and totaled $1,932,706 as compared to $1,212,513 for the same period in 2016. While revenue decreased $11,523, the Company experienced an $862,730 net increase in expenses. The Company recorded other income of $201,774, primarily from the receipt of New Mexico state employee incentives, and non-cash income and expenses related to derivative liabilities and debt discounts.
As of June 30, 2017, the Company had $3,384,499 in cash on its balance sheet, compared to $398,391 in cash as of June 30, 2016 and a working capital surplus of $3,374,359 as of June 30, 2017, compared to a working capital surplus of $110,799 as of June 30, 2016.
Investor Conference CallManagement will host a conference call today, Monday, August 14, 2017 at 4:30pm to review financial results and corporate highlights. Following management’s formal remarks, there will be a question and answer session. To listen to the call by phone, interested parties within the U.S. should call 1-877-344-7529 and International callers should call 1-412-317-5134. All callers should ask for the Sigma Labs conference call. The conference call will also be available through a live webcast at www.sigmalabsinc.com. Details for the webcast may be found on the Company’s IR events page at http://client.irwebkit.com/sigmalabsinc/events. A replay of the call will be available approximately one hour after the end of the call through September 14, 2017. The replay can be accessed via Sigma Labs' website or by dialing 877-344-7529 (domestic) or 412-317-0088 (international) or Canada Toll Free at 855-669-9658. The replay conference ID number is 10111326. The webcast replay will be available through November 14, 2017.
About Sigma Labs, Inc. Sigma Labs, Inc. is a provider of quality assurance software under the PrintRite3D® brand and a developer of advanced, in-process, non-destructive quality assurance software for commercial firms worldwide seeking productive solutions for advanced manufacturing. For more information please visit us at www.sigmalabsinc.com.
Forward-Looking StatementsThis press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Annual Report on Form 10-K (including but not limited to the discussion under “Risk Factors” therein) filed with the SEC on March 31, 2017 and which may be viewed at http://www.sec.gov.
Sigma Labs, Inc. | ||||||||
Condensed Balance Sheets | ||||||||
(Unaudited) | ||||||||
June 30, 2017 | December 31, 2016 | |||||||
ASSETS | ||||||||
Current Assets: | ||||||||
Cash | $ | 3,384,499 | $ | 398,391 | ||||
Accounts Receivable, net | 235,467 | 288,236 | ||||||
Note Receivable, net | 762,034 | - | ||||||
Inventory | 227,827 | 187,241 | ||||||
Prepaid Assets | 37,176 | 36,056 | ||||||
Total Current Assets | 4,647,003 | 909,924 | ||||||
Other Assets: | ||||||||
Property and Equipment, net | 491,188 | 564,933 | ||||||
Intangible Assets, net | 241,978 | 226,450 | ||||||
Investment in Joint Venture | 500 | 500 | ||||||
Prepaid Stock Compensation | 111,070 | 167,562 | ||||||
Total Other Assets | 844,736 | 959,445 | ||||||
TOTAL ASSETS | $ | 5,491,739 | $ | 1,869,369 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current Liabilities: | ||||||||
Accounts Payable | 137,605 | 112,175 | ||||||
Notes Payable, net of original issue discount $30,297 atJune 30, 2017 and net of original issue discount$69,703 and net of debt discount $358,280 atDecember 31, 2016 | 969,703 | 561,834 | ||||||
Accrued Expenses | 165,336 | 125,116 | ||||||
Total Current Liabilities | 1,272,644 | 799,125 | ||||||
Long-Term Liabilities | ||||||||
Derivative Liability | - | 93,206 | ||||||
Total Long-Term Liability | - | 93,206 | ||||||
TOTAL LIABILITIES | 1,272,644 | 892,331 | ||||||
Stockholders' Equity | ||||||||
Preferred Stock, $0.001 par; 10,000,000 sharesauthorized; | ||||||||
None issued and outstanding | - | - | ||||||
Common Stock, $0.001 par; 7,500,000 sharesauthorized; | ||||||||
4,570,199 and 3,133,789 issued and outstanding at June 30, 2017 and 2016, respectively | 4,570 | 3,135 | ||||||
Additional Paid-In Capital | 15,908,185 | 10,734,857 | ||||||
Accumulated Deficit | (11,693,660 | ) | (9,760,954 | ) | ||||
Total Stockholders' Equity | 4,219,095 | 977,038 | ||||||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 5,491,739 | $ | 1,869,369 | ||||
Sigma Labs, Inc. | ||||||||||||
Condensed Statements of Operations | ||||||||||||
(Unaudited) | ||||||||||||
Three Months Ended | Six Months Ended | |||||||||||
June 30,2017 | June 30,2016 | June 30,2017 | June 30,2016 | |||||||||
Revenues | $ | 290,553 | $ | 93,824 | $ | 440,756 | $ | 452,279 | ||||
COST OF REVENUE | $ | 111,412 | 30,904 | 185,946 | 138,485 | |||||||
GROSS PROFIT | 179,141 | 62,920 | 254,810 | 313,794 | ||||||||
EXPENSES: | ||||||||||||
Other General and Administration | 594,193 | 480,697 | 1,237,988 | 876,185 | ||||||||
Payroll Expense | 300,661 | 252,895 | 677,282 | 468,484 | ||||||||
Stock-Based Compensation | 166,773 | 59,362 | 306,405 | 130,913 | ||||||||
Research and Development | 118,853 | 11,907 | 167,615 | 50,978 | ||||||||
Total Expenses | 1,180,480 | 804,861 | 2,389,290 | 1,526,560 | ||||||||
OTHER INCOME (EXPENSE) | ||||||||||||
Interest Income | 12,598 | 95 | 12,941 | 253 | ||||||||
Other Income | - | - | 152,068 | - | ||||||||
Other Income-Decrease in fair value of derivative liabilities | - | - | 93,206 | - | ||||||||
Other Expense - Debt discount amortization | - | - | (56,441 | ) | - | |||||||
Total Other Income | 12,598 | 95 | 201,774 | 253 | ||||||||
LOSS BEFORE PROVISION FOR INCOME TAXES | (988,741 | ) | (741,846 | ) | (1,932,706 | ) | (1,212,513 | ) | ||||
Provision for income Taxes | - | - | - | - | ||||||||
Net Loss | $ | (988,741 | ) | $ | (741,846 | ) | $ | (1,932,706 | ) | $ | (1,212,513 | ) |
Net Loss per Common Share - Basic and Diluted | $ | (0.22 | ) | $ | (0.24 | ) | $ | (0.46 | ) | $ | (0.38 | ) |
Weighted Average Number of Shares | ||||||||||||
Outstanding - Basic and Diluted | 4,570,199 | 3,117,851 | 4,207,116 | 3,117,851 | ||||||||
Sigma Labs, Inc. | |||||||||
Condensed Statements of Cash Flows | |||||||||
(Unaudited) | |||||||||
Six Months ended | |||||||||
2017 | 2016 | ||||||||
OPERATING ACTIVITIES | |||||||||
Net Loss | $ | (1,932,706 | ) | $ | (1,212,513 | ) | |||
Adjustments to reconcile Net Income (Loss) to Net Cashused in operating activities: | |||||||||
Noncash Expenses: | |||||||||
Amortization | 6,526 | 5,764 | |||||||
Depreciation | 85,125 | 87,054 | |||||||
Stock Compensation | 307,445 | 130,913 | |||||||
Loss on Joint Venture | - | 103 | |||||||
Revaluation of derivative liability and debt discount related tonotes payable | (93,206 | ) | - | ||||||
Note payable original issue discount | 49,589 | - | |||||||
Note payable debt discount amortization | 56,441 | - | |||||||
Change in assets and liabilities: | |||||||||
Accounts Receivable | 52,769 | 27,564 | |||||||
Inventory | (40,586 | ) | (70,765 | ) | |||||
Prepaid Assets | (1,120 | ) | 7,344 | ||||||
Accounts Payable | 25,430 | 63,974 | |||||||
Accrued Expenses | 40,220 | 46,006 | |||||||
NET CASH USED IN OPERATING ACTIVITIES | (1,444,073 | ) | (914,556 | ) | |||||
INVESTING ACTIVITIES | |||||||||
Purchase of Furniture and Equipment | (11,380 | ) | (25,430 | ) | |||||
Purchase of Intangible Assets | (22,054 | ) | (46,835 | ) | |||||
Notes receivable | (762,034 | ) | - | ||||||
NET CASH USED IN INVESTING ACTIVITIES | (795,468 | ) | (72,265 | ) | |||||
FINANCING ACTIVITIES | |||||||||
Proceeds from issuance of common stock and warrants | 5,225,649 | - | |||||||
NET CASH PROVIDED BY FINANCING ACTIVITIES | 5,225,649 | - | |||||||
NET CASH DECREASE FOR PERIOD | 2,986,108 | (986,821 | ) | ||||||
CASH AT BEGINNING OF PERIOD | 398,391 | 1,539,809 | |||||||
CASH AT END OF PERIOD | $ | 3,384,499 | $ | 552,988 | |||||
Supplemental Disclosure of Cash Flow Information: | |||||||||
Cash paid during the period for: | |||||||||
Interest | $ | 50,418 | $ | - | |||||
Income Taxes | $ | - | $ | - | |||||
Supplemental Schedule of Noncash Investing and Financing Activities: | |||||||||
Issuance of Common Stock for services | $ | 51,408 | $ | 44,998 | |||||
Investor Relations Contact: Bret Shapiro Managing Director CORE IR 561-479-8566 brets@coreir.com
1 Year Sigma Labs Chart |
1 Month Sigma Labs Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions